MedNews Week Keynote - New Therapies for Myeloproliferative Neoplasms - Dr. Ruben Mesa

Описание: Myeloproliferative neoplasms (MPN) are a class of rare disorders of the bone marrow leading to an increased production of blood cells. It has been estimated that 20,000 people are diagnosed every year, with over 295,000 in the US. Join Keynote Speaker & Global Authority, Dr. Ruben A. Mesa – Executive Director of Mays Cancer Center at UT Health San Antonio MD Anderson- as he discusses the latest developments in New Therapies for Myeloproliferative Neoplasms.

Career Highlights

· Global Authority on Myeloproliferative neoplasms (MPN) & Experimental Therapeutics.
· International leader in Phase I-III clinical trials in therapeutic interventions against MPN who has directed over 100 clinical trials internationally.
· Co-leader who contributed to the US FDA’s approval of ruxolitinib for polycythemia vera and myelofibrosis, and fedratinib for myelofibrosis.
· Led the development of the first U.S. National Comprehensive Cancer Network’s panel guidelines for the diagnosis and treatment of myelofibrosis, polycythemia vera & essential thrombocythemia.
· Co-leads the NCI P01 funded MPN Research Consortium.
· Recognized as:
Texas’s Top Doctors (2020).
Best San Antonio Doctors (2020).
Cancer Care’s Physician of the Year Award (2015)
Top Oncologist in Scottsdale Arizona (2014)
Phenix Super Doctors: AZ Magazine (2012)
· Recipient of:
The Career Award- MPN Translational Research 20th Annual MPN Congress: Awarded for Career Excellence in Translational Research in (2021).
MPN Advocacy & Education Career Recognition Award (2019)
Top Faculty Award in Mayo Clinic (2011-2014)
Mayo Clinic Investigator of the Year Award (2013)
· Published the Treatment Strategies Series at the Cambridge Research Centre.
· Currently serving as:
National Board Member and member of the Executive Committee of the Board of the Leukemia and Lymphoma Society.
Board of Directors and Chief Medical Advisor of the MPN Education Foundation.
Board of the Directors of the American Association of Cancer Institutes (AACI).
Member of the National Cancer Institute (NCI) Clinical Trial Advisory Committee (CTAC).
Editorial Board Member of the Journals; Advances in Cell and Gene Therapy, HemOnc Today, European Medical Journal-Haematology Member, American Journal of Hematology/Oncology, Cambridge Research Centre
Member of the Mayo Clinic Research Committee.
Member of the MD Anderson Cancer Centre Moonshot and Review panel MD Aderson Cancer Centre.
Co-chair of the Global Research Award Program, American Society of Hematology.